La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Laboratorios Farmaceuticos Rovi Croissance future
Future contrôle des critères 5/6
Laboratorios Farmaceuticos Rovi devrait augmenter ses bénéfices et son chiffre d'affaires de 22.2% et de 11.6% par an respectivement. Le BPA devrait croître de de 21% par an. Le rendement des capitaux propres devrait être 30.4% dans 3 ans.
Informations clés
22.2%
Taux de croissance des bénéfices
21.0%
Taux de croissance du BPA
Pharmaceuticals croissance des bénéfices | 15.3% |
Taux de croissance des recettes | 11.6% |
Rendement futur des capitaux propres | 30.4% |
Couverture par les analystes | Good |
Dernière mise à jour | 06 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Jul 15We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet
Jun 17Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price
May 08These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Apr 17Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?
Feb 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Dec 21Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?
Nov 03Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Aug 26Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jul 14Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
May 26Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?
May 05Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate
Apr 11Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Feb 22An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued
Dec 10These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Nov 04Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
Sep 15Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Aug 28Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Jun 15I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease
Feb 13Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Jan 02A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Dec 12Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Nov 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Sep 24Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Jun 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Apr 06Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%
Mar 15If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late
Feb 16Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?
Jan 26These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Jan 04Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years
Dec 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?
Nov 26Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jul 06Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 1,046 | 269 | 200 | 245 | 6 |
12/31/2025 | 890 | 201 | 165 | 206 | 6 |
12/31/2024 | 817 | 164 | 162 | 229 | 6 |
6/30/2024 | 778 | 148 | 35 | 90 | N/A |
3/31/2024 | 779 | 138 | 45 | 104 | N/A |
12/31/2023 | 830 | 170 | 58 | 113 | N/A |
9/30/2023 | 837 | 197 | 60 | 120 | N/A |
6/30/2023 | 818 | 186 | 61 | 121 | N/A |
3/31/2023 | 814 | 194 | 104 | 158 | N/A |
12/31/2022 | 818 | 200 | 186 | 238 | N/A |
9/30/2022 | 761 | 176 | 144 | 182 | N/A |
6/30/2022 | 739 | 183 | 192 | 232 | N/A |
3/31/2022 | 724 | 182 | 190 | 229 | N/A |
12/31/2021 | 649 | 153 | 109 | 149 | N/A |
9/30/2021 | 581 | 113 | 145 | 189 | N/A |
6/30/2021 | 519 | 82 | 105 | 149 | N/A |
3/31/2021 | 450 | 71 | 31 | 72 | N/A |
12/31/2020 | 420 | 61 | 7 | 47 | N/A |
9/30/2020 | 413 | 55 | -37 | -7 | N/A |
6/30/2020 | 395 | 53 | -52 | -27 | N/A |
3/31/2020 | 400 | 46 | -34 | -7 | N/A |
12/31/2019 | 381 | 39 | -50 | -9 | N/A |
9/30/2019 | 355 | 33 | -39 | 6 | N/A |
6/30/2019 | 334 | 27 | -31 | 12 | N/A |
3/31/2019 | 310 | 18 | -38 | 3 | N/A |
12/31/2018 | 303 | 18 | -18 | 9 | N/A |
9/30/2018 | 291 | 16 | -13 | 8 | N/A |
6/30/2018 | 283 | 9 | -4 | 16 | N/A |
3/31/2018 | 284 | 18 | N/A | 30 | N/A |
12/31/2017 | 276 | 17 | N/A | 18 | N/A |
9/30/2017 | 277 | 22 | N/A | 21 | N/A |
6/30/2017 | 275 | 24 | N/A | 25 | N/A |
3/31/2017 | 272 | 23 | N/A | 24 | N/A |
12/31/2016 | 265 | 26 | N/A | 46 | N/A |
9/30/2016 | 260 | 25 | N/A | 44 | N/A |
6/30/2016 | 254 | 24 | N/A | 38 | N/A |
3/31/2016 | 246 | 23 | N/A | 40 | N/A |
12/31/2015 | 246 | 20 | N/A | 29 | N/A |
9/30/2015 | 242 | 21 | N/A | 22 | N/A |
6/30/2015 | 243 | 23 | N/A | 27 | N/A |
3/31/2015 | 241 | 25 | N/A | 29 | N/A |
12/31/2014 | 238 | 24 | N/A | 23 | N/A |
9/30/2014 | 230 | 24 | N/A | 30 | N/A |
6/30/2014 | 224 | 24 | N/A | 28 | N/A |
3/31/2014 | 221 | 24 | N/A | 20 | N/A |
12/31/2013 | 218 | 23 | N/A | 30 | N/A |
9/30/2013 | 209 | 22 | N/A | 19 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de ROVI ( 22.2% par an) est supérieure au taux d'épargne ( 1.7% ).
Bénéfices vs marché: Les bénéfices de ROVI ( 22.2% par an) devraient croître plus rapidement que le marché Spanish ( 9.6% par an).
Croissance élevée des bénéfices: Les bénéfices de ROVI devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de ROVI ( 11.6% par an) devrait croître plus rapidement que le marché Spanish ( 4.7% par an).
Croissance élevée des revenus: Le chiffre d'affaires de ROVI ( 11.6% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de ROVI devrait être élevé dans 3 ans ( 30.4 %)